Listed

Edesa Biotech, Inc.

EDSANasdaqCIK 1540159HealthcareFiscal year ends Sep 30

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Operating income−$5.5m, Q3 FY2026
Net income−$5.4m, Q3 FY2026
Edesa Biotech, Inc., income statement, quarterly
Line itemUnitQ4 FY20232023-09-30Q1 FY20242023-12-31Q2 FY20242024-03-31Q3 FY20242024-06-30Q4 FY20242024-09-30Q1 FY20252024-12-31Q2 FY20252025-03-31Q3 FY20252025-06-30Q4 FY20252025-09-30Q1 FY20262025-12-31Q2 FY20262026-03-31Q3 FY20262026-06-30
Revenue$knot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Cost of revenue$knot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Research and development$k953Research and development, Q4 FY2023, three months to 2023-09-30$953.4k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2024-12-13, accession 0001171843-24-006946. Derived: 12-month figure less the 9-month figure.Report this figure704Research and development, Q1 FY2024, three months to 2023-12-31$704.5k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-02-14, accession 0001171843-25-000866.Report this figure1,176Research and development, Q2 FY2024, three months to 2024-03-31$1.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-14, accession 0001171843-25-003189.Report this figure897Research and development, Q3 FY2024, three months to 2024-06-30$897.3k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-08, accession 0001171843-25-005236.Report this figure104Research and development, Q4 FY2024, three months to 2024-09-30$103.9k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-12-12, accession 0001171843-25-007914. Derived: 12-month figure less the 9-month figure.Report this figure1,020Research and development, Q1 FY2025, three months to 2024-12-31$1.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-02-13, accession 0001171843-26-000812.Report this figure484Research and development, Q2 FY2025, three months to 2025-03-31$484.3k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-14, accession 0001171843-26-003433.Report this figure939Research and development, Q3 FY2025, three months to 2025-06-30$939.1k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-13, accession 0001171843-26-005502.Report this figure1,226Research and development, Q4 FY2025, three months to 2025-09-30$1.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-12-12, accession 0001171843-25-007914. Derived: 12-month figure less the 9-month figure.Report this figure1,125Research and development, Q1 FY2026, three months to 2025-12-31$1.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-02-13, accession 0001171843-26-000812.Report this figure2,767Research and development, Q2 FY2026, three months to 2026-03-31$2.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-14, accession 0001171843-26-003433.Report this figure3,958Research and development, Q3 FY2026, three months to 2026-06-30$4.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-13, accession 0001171843-26-005502.Report this figure
Operating income$k(2,370)Operating income, Q4 FY2023, three months to 2023-09-30−$2.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-12-13, accession 0001171843-24-006946. Derived: 12-month figure less the 9-month figure.Report this figure(1,857)Operating income, Q1 FY2024, three months to 2023-12-31−$1.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-02-14, accession 0001171843-25-000866.Report this figure(2,220)Operating income, Q2 FY2024, three months to 2024-03-31−$2.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-14, accession 0001171843-25-003189.Report this figure(1,932)Operating income, Q3 FY2024, three months to 2024-06-30−$1.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-08, accession 0001171843-25-005236.Report this figure(1,004)Operating income, Q4 FY2024, three months to 2024-09-30−$1.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-12-12, accession 0001171843-25-007914. Derived: 12-month figure less the 9-month figure.Report this figure(1,899)Operating income, Q1 FY2025, three months to 2024-12-31−$1.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-02-13, accession 0001171843-26-000812.Report this figure(1,639)Operating income, Q2 FY2025, three months to 2025-03-31−$1.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-14, accession 0001171843-26-003433.Report this figure(1,904)Operating income, Q3 FY2025, three months to 2025-06-30−$1.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-13, accession 0001171843-26-005502.Report this figure(2,470)Operating income, Q4 FY2025, three months to 2025-09-30−$2.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-12-12, accession 0001171843-25-007914. Derived: 12-month figure less the 9-month figure.Report this figure(2,341)Operating income, Q1 FY2026, three months to 2025-12-31−$2.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-02-13, accession 0001171843-26-000812.Report this figure(4,297)Operating income, Q2 FY2026, three months to 2026-03-31−$4.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-14, accession 0001171843-26-003433.Report this figure(5,520)Operating income, Q3 FY2026, three months to 2026-06-30−$5.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-13, accession 0001171843-26-005502.Report this figure
Income tax$k0.0Income tax, Q4 FY2023, three months to 2023-09-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2024-12-13, accession 0001171843-24-006946. Derived: 12-month figure less the 9-month figure.Report this figurenot reported0.8Income tax, Q2 FY2024, three months to 2024-03-31$800. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-05-14, accession 0001171843-25-003189.Report this figure0.0Income tax, Q3 FY2024, three months to 2024-06-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-08-08, accession 0001171843-25-005236.Report this figure0.0Income tax, Q4 FY2024, three months to 2024-09-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2025-12-12, accession 0001171843-25-007914. Derived: 12-month figure less the 9-month figure.Report this figurenot reported0.8Income tax, Q2 FY2025, three months to 2025-03-31$800. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-05-14, accession 0001171843-26-003433.Report this figure0.0Income tax, Q3 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-13, accession 0001171843-26-005502.Report this figure0.0Income tax, Q4 FY2025, three months to 2025-09-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2025-12-12, accession 0001171843-25-007914. Derived: 12-month figure less the 9-month figure.Report this figurenot reported0.8Income tax, Q2 FY2026, three months to 2026-03-31$800. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-05-14, accession 0001171843-26-003433.Report this figure0.0Income tax, Q3 FY2026, three months to 2026-06-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-13, accession 0001171843-26-005502.Report this figure
Net income$k(1,720)Net income, Q4 FY2023, three months to 2023-09-30−$1.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-12-13, accession 0001171843-24-006946. Derived: 12-month figure less the 9-month figure.Report this figure(1,678)Net income, Q1 FY2024, three months to 2023-12-31−$1.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-02-14, accession 0001171843-25-000866.Report this figure(1,861)Net income, Q2 FY2024, three months to 2024-03-31−$1.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-05-14, accession 0001171843-25-003189.Report this figure(1,668)Net income, Q3 FY2024, three months to 2024-06-30−$1.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-08-08, accession 0001171843-25-005236.Report this figure(962)Net income, Q4 FY2024, three months to 2024-09-30−$962.1k. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-12-12, accession 0001171843-25-007914. Derived: 12-month figure less the 9-month figure.Report this figure(1,617)Net income, Q1 FY2025, three months to 2024-12-31−$1.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-02-13, accession 0001171843-26-000812.Report this figure(1,590)Net income, Q2 FY2025, three months to 2025-03-31−$1.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-14, accession 0001171843-26-003433.Report this figure(1,749)Net income, Q3 FY2025, three months to 2025-06-30−$1.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001171843-26-005502.Report this figure(2,228)Net income, Q4 FY2025, three months to 2025-09-30−$2.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-12-12, accession 0001171843-25-007914. Derived: 12-month figure less the 9-month figure.Report this figure(2,248)Net income, Q1 FY2026, three months to 2025-12-31−$2.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-02-13, accession 0001171843-26-000812.Report this figure(4,218)Net income, Q2 FY2026, three months to 2026-03-31−$4.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-14, accession 0001171843-26-003433.Report this figure(5,408)Net income, Q3 FY2026, three months to 2026-06-30−$5.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001171843-26-005502.Report this figure
Diluted EPS$ per sharenot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Basic EPS$ per sharenot reported(0.54)Basic EPS, Q1 FY2024, three months to 2023-12-31−$0.54 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-02-14, accession 0001171843-25-000866.Report this figure(0.58)Basic EPS, Q2 FY2024, three months to 2024-03-31−$0.58 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-14, accession 0001171843-25-003189.Report this figure(0.52)Basic EPS, Q3 FY2024, three months to 2024-06-30−$0.52 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-08, accession 0001171843-25-005236.Report this figurenot reported(0.48)Basic EPS, Q1 FY2025, three months to 2024-12-31−$0.48 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-02-13, accession 0001171843-26-000812.Report this figure(0.30)Basic EPS, Q2 FY2025, three months to 2025-03-31−$0.30 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-14, accession 0001171843-26-003433.Report this figure(0.25)Basic EPS, Q3 FY2025, three months to 2025-06-30−$0.25 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-13, accession 0001171843-26-005502.Report this figurenot reported(0.28)Basic EPS, Q1 FY2026, three months to 2025-12-31−$0.28 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-02-13, accession 0001171843-26-000812.Report this figure(0.49)Basic EPS, Q2 FY2026, three months to 2026-03-31−$0.49 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-14, accession 0001171843-26-003433.Report this figure(0.60)Basic EPS, Q3 FY2026, three months to 2026-06-30−$0.60 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-13, accession 0001171843-26-005502.Report this figure

Balance sheet

Cash and equivalents$10.3m, Q3 FY2026
Shareholders' equity$8.8m, Q3 FY2026
Edesa Biotech, Inc., balance sheet, quarterly
Line itemUnitFY20232023-09-30Q1 FY20242023-12-31Q2 FY20242024-03-31Q3 FY20242024-06-30FY20242024-09-30Q1 FY20252024-12-31Q2 FY20252025-03-31Q3 FY20252025-06-30FY20252025-09-30Q1 FY20262025-12-31Q2 FY20262026-03-31Q3 FY20262026-06-30
Cash and equivalents$m5.4Cash and equivalents, FY2023, at 2023-09-30$5.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2023-12-15, accession 0001654954-23-015632.Report this figurenot reportednot reportednot reported1.0Cash and equivalents, FY2024, at 2024-09-30$1.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2024-12-13, accession 0001171843-24-006946.Report this figure1.6Cash and equivalents, Q1 FY2025, at 2024-12-31$1.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-02-14, accession 0001171843-25-000866.Report this figure13.9Cash and equivalents, Q2 FY2025, at 2025-03-31$13.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-14, accession 0001171843-25-003189.Report this figure12.4Cash and equivalents, Q3 FY2025, at 2025-06-30$12.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-08, accession 0001171843-25-005236.Report this figure10.8Cash and equivalents, FY2025, at 2025-09-30$10.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-12-12, accession 0001171843-25-007914.Report this figure12.1Cash and equivalents, Q1 FY2026, at 2025-12-31$12.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-02-13, accession 0001171843-26-000812.Report this figure10.0Cash and equivalents, Q2 FY2026, at 2026-03-31$10.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-14, accession 0001171843-26-003433.Report this figure10.3Cash and equivalents, Q3 FY2026, at 2026-06-30$10.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-13, accession 0001171843-26-005502.Report this figure
Current assets$m6.4Current assets, FY2023, at 2023-09-30$6.4m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2024-12-13, accession 0001171843-24-006946.Report this figure5.4Current assets, Q1 FY2024, at 2023-12-31$5.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-02-09, accession 0001654954-24-001540.Report this figure4.2Current assets, Q2 FY2024, at 2024-03-31$4.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-10, accession 0001654954-24-005971.Report this figure3.0Current assets, Q3 FY2024, at 2024-06-30$3.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-09, accession 0001171843-24-004651.Report this figure1.7Current assets, FY2024, at 2024-09-30$1.7m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-12-12, accession 0001171843-25-007914.Report this figure2.1Current assets, Q1 FY2025, at 2024-12-31$2.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-02-14, accession 0001171843-25-000866.Report this figure14.4Current assets, Q2 FY2025, at 2025-03-31$14.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-14, accession 0001171843-25-003189.Report this figure12.8Current assets, Q3 FY2025, at 2025-06-30$12.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-08, accession 0001171843-25-005236.Report this figure11.5Current assets, FY2025, at 2025-09-30$11.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-13, accession 0001171843-26-005502.Report this figure12.7Current assets, Q1 FY2026, at 2025-12-31$12.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-02-13, accession 0001171843-26-000812.Report this figure10.4Current assets, Q2 FY2026, at 2026-03-31$10.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-14, accession 0001171843-26-003433.Report this figure10.8Current assets, Q3 FY2026, at 2026-06-30$10.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-13, accession 0001171843-26-005502.Report this figure
Total assets$m8.9Total assets, FY2023, at 2023-09-30$8.9m. XBRL concept us-gaap:Assets. 10-K filed 2024-12-13, accession 0001171843-24-006946.Report this figure7.8Total assets, Q1 FY2024, at 2023-12-31$7.8m. XBRL concept us-gaap:Assets. 10-Q filed 2024-02-09, accession 0001654954-24-001540.Report this figure6.5Total assets, Q2 FY2024, at 2024-03-31$6.5m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-10, accession 0001654954-24-005971.Report this figure5.2Total assets, Q3 FY2024, at 2024-06-30$5.2m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-09, accession 0001171843-24-004651.Report this figure3.8Total assets, FY2024, at 2024-09-30$3.8m. XBRL concept us-gaap:Assets. 10-K filed 2025-12-12, accession 0001171843-25-007914.Report this figure4.2Total assets, Q1 FY2025, at 2024-12-31$4.2m. XBRL concept us-gaap:Assets. 10-Q filed 2025-02-14, accession 0001171843-25-000866.Report this figure16.5Total assets, Q2 FY2025, at 2025-03-31$16.5m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-14, accession 0001171843-25-003189.Report this figure14.8Total assets, Q3 FY2025, at 2025-06-30$14.8m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-08, accession 0001171843-25-005236.Report this figure13.5Total assets, FY2025, at 2025-09-30$13.5m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-13, accession 0001171843-26-005502.Report this figure14.7Total assets, Q1 FY2026, at 2025-12-31$14.7m. XBRL concept us-gaap:Assets. 10-Q filed 2026-02-13, accession 0001171843-26-000812.Report this figure12.4Total assets, Q2 FY2026, at 2026-03-31$12.4m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-14, accession 0001171843-26-003433.Report this figure12.7Total assets, Q3 FY2026, at 2026-06-30$12.7m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-13, accession 0001171843-26-005502.Report this figure
Current liabilities$m1.8Current liabilities, FY2023, at 2023-09-30$1.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2024-12-13, accession 0001171843-24-006946.Report this figure2.0Current liabilities, Q1 FY2024, at 2023-12-31$2.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-02-09, accession 0001654954-24-001540.Report this figure2.2Current liabilities, Q2 FY2024, at 2024-03-31$2.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-10, accession 0001654954-24-005971.Report this figure2.4Current liabilities, Q3 FY2024, at 2024-06-30$2.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-09, accession 0001171843-24-004651.Report this figure1.8Current liabilities, FY2024, at 2024-09-30$1.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-12-12, accession 0001171843-25-007914.Report this figure1.9Current liabilities, Q1 FY2025, at 2024-12-31$1.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-02-14, accession 0001171843-25-000866.Report this figure0.9Current liabilities, Q2 FY2025, at 2025-03-31$914.7k. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-14, accession 0001171843-25-003189.Report this figure0.7Current liabilities, Q3 FY2025, at 2025-06-30$672.7k. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-08, accession 0001171843-25-005236.Report this figure1.1Current liabilities, FY2025, at 2025-09-30$1.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-13, accession 0001171843-26-005502.Report this figure0.8Current liabilities, Q1 FY2026, at 2025-12-31$756.2k. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-02-13, accession 0001171843-26-000812.Report this figure2.2Current liabilities, Q2 FY2026, at 2026-03-31$2.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-14, accession 0001171843-26-003433.Report this figure3.9Current liabilities, Q3 FY2026, at 2026-06-30$3.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-13, accession 0001171843-26-005502.Report this figure
Total liabilities$m1.8Total liabilities, FY2023, at 2023-09-30$1.8m. XBRL concept us-gaap:Liabilities. 10-K filed 2024-12-13, accession 0001171843-24-006946.Report this figure2.0Total liabilities, Q1 FY2024, at 2023-12-31$2.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-02-09, accession 0001654954-24-001540.Report this figure2.2Total liabilities, Q2 FY2024, at 2024-03-31$2.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-10, accession 0001654954-24-005971.Report this figure2.4Total liabilities, Q3 FY2024, at 2024-06-30$2.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-09, accession 0001171843-24-004651.Report this figure1.8Total liabilities, FY2024, at 2024-09-30$1.8m. XBRL concept us-gaap:Liabilities. 10-K filed 2024-12-13, accession 0001171843-24-006946.Report this figurenot reportednot reportednot reportednot reportednot reportednot reportednot reported
Shareholders' equity$m7.0Shareholders' equity, FY2023, at 2023-09-30$7.0m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2025-12-12, accession 0001171843-25-007914.Report this figure5.8Shareholders' equity, Q1 FY2024, at 2023-12-31$5.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-05-14, accession 0001171843-25-003189.Report this figure4.3Shareholders' equity, Q2 FY2024, at 2024-03-31$4.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-08-08, accession 0001171843-25-005236.Report this figure2.9Shareholders' equity, Q3 FY2024, at 2024-06-30$2.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-08-08, accession 0001171843-25-005236.Report this figure2.0Shareholders' equity, FY2024, at 2024-09-30$2.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001171843-26-005502.Report this figure2.3Shareholders' equity, Q1 FY2025, at 2024-12-31$2.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-05-14, accession 0001171843-26-003433.Report this figure15.5Shareholders' equity, Q2 FY2025, at 2025-03-31$15.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001171843-26-005502.Report this figure14.1Shareholders' equity, Q3 FY2025, at 2025-06-30$14.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001171843-26-005502.Report this figure12.5Shareholders' equity, FY2025, at 2025-09-30$12.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001171843-26-005502.Report this figure14.0Shareholders' equity, Q1 FY2026, at 2025-12-31$14.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-05-14, accession 0001171843-26-003433.Report this figure10.2Shareholders' equity, Q2 FY2026, at 2026-03-31$10.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001171843-26-005502.Report this figure8.8Shareholders' equity, Q3 FY2026, at 2026-06-30$8.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001171843-26-005502.Report this figure

Cash flow

Operating cash flow−$3.1m, Q3 FY2026
Capital expenditure$0, Q4 FY2023
Edesa Biotech, Inc., cash flow, quarterly
Line itemUnitQ4 FY20232023-09-30Q1 FY20242023-12-31Q2 FY20242024-03-31Q3 FY20242024-06-30Q4 FY20242024-09-30Q1 FY20252024-12-31Q2 FY20252025-03-31Q3 FY20252025-06-30Q4 FY20252025-09-30Q1 FY20262025-12-31Q2 FY20262026-03-31Q3 FY20262026-06-30
Operating cash flow$k(1,468)Operating cash flow, Q4 FY2023, three months to 2023-09-30−$1.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-12-13, accession 0001171843-24-006946. Derived: 12-month figure less the 9-month figure.Report this figure(1,407)Operating cash flow, Q1 FY2024, three months to 2023-12-31−$1.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-02-14, accession 0001171843-25-000866.Report this figure(1,660)Operating cash flow, Q2 FY2024, three months to 2024-03-31−$1.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-14, accession 0001171843-25-003189. Derived: 6-month figure less the 3-month figure.Report this figure(856)Operating cash flow, Q3 FY2024, three months to 2024-06-30−$856.5k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-08, accession 0001171843-25-005236. Derived: 9-month figure less the 6-month figure.Report this figure(967)Operating cash flow, Q4 FY2024, three months to 2024-09-30−$967.0k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-12-12, accession 0001171843-25-007914. Derived: 12-month figure less the 9-month figure.Report this figure(1,517)Operating cash flow, Q1 FY2025, three months to 2024-12-31−$1.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-02-13, accession 0001171843-26-000812.Report this figure(2,383)Operating cash flow, Q2 FY2025, three months to 2025-03-31−$2.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-14, accession 0001171843-26-003433. Derived: 6-month figure less the 3-month figure.Report this figure(1,701)Operating cash flow, Q3 FY2025, three months to 2025-06-30−$1.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-13, accession 0001171843-26-005502. Derived: 9-month figure less the 6-month figure.Report this figure(1,721)Operating cash flow, Q4 FY2025, three months to 2025-09-30−$1.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-12-12, accession 0001171843-25-007914. Derived: 12-month figure less the 9-month figure.Report this figure(2,087)Operating cash flow, Q1 FY2026, three months to 2025-12-31−$2.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-02-13, accession 0001171843-26-000812.Report this figure(2,017)Operating cash flow, Q2 FY2026, three months to 2026-03-31−$2.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-14, accession 0001171843-26-003433. Derived: 6-month figure less the 3-month figure.Report this figure(3,083)Operating cash flow, Q3 FY2026, three months to 2026-06-30−$3.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-13, accession 0001171843-26-005502. Derived: 9-month figure less the 6-month figure.Report this figure
Capital expenditure$k0.0Capital expenditure, Q4 FY2023, three months to 2023-09-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2023-12-15, accession 0001654954-23-015632. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported

Shares

Diluted shares (weighted)8.45m, Q3 FY2016
Edesa Biotech, Inc., shares, quarterly
Line itemUnitperiod not labelled2013-12-31period not labelled2014-03-31period not labelled2014-06-30Q1 FY20152014-12-31Q2 FY20152015-03-31Q3 FY20152015-06-30Q3 FY20162016-06-30
Diluted shares (weighted)m shares74.0Diluted shares (weighted), period not labelled, three months to 2013-12-3173,978,736 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2015-02-09, accession 0001144204-15-007126.Report this figure76.2Diluted shares (weighted), period not labelled, three months to 2014-03-3176,237,455 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2015-05-11, accession 0001144204-15-029347.Report this figure86.9Diluted shares (weighted), period not labelled, three months to 2014-06-3086,898,996 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2015-08-10, accession 0001144204-15-047755.Report this figure79.5Diluted shares (weighted), Q1 FY2015, three months to 2014-12-3179,461,013 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2015-02-09, accession 0001144204-15-007126.Report this figure79.5Diluted shares (weighted), Q2 FY2015, three months to 2015-03-3179,546,650 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2015-05-11, accession 0001144204-15-029347.Report this figure8.5Diluted shares (weighted), Q3 FY2015, three months to 2015-06-308,502,035 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2016-08-09, accession 0001144204-16-117445.Report this figure8.4Diluted shares (weighted), Q3 FY2016, three months to 2016-06-308,448,758 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2016-08-09, accession 0001144204-16-117445.Report this figure

Shares outstanding: 9.64mShares outstanding, period not labelled, at 2026-08-139,641,031 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-13, accession 0001171843-26-005502.Report this figure at Aug 13, 2026, from the cover of the 10-Q filed Aug 13, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:42 ET. Listed shows no prices and gives no investment advice.